Welcome, visitor! [ Register | LoginRSS Feed

 

$6,994,496.00

Immune Checkpoint Inhibitors Boston

  • Abbreviation: ICI Boston will help you leverage the new understanding of pathway biology and biomarker strategy in the development of your checkpoint drugs.
  • Conference Type: Conference
  • Start Date: On Tuesday March 15, 2016 at 9:00 am to Thursday March 17, 2016 at 5:00 pm
  • Online Registration: http://atnd.it/42080-1
  • Conference URL: http://atnd.it/42080-0
  • Hotel Venue: Revere Hotel Boston Common
  • Street: 200 Stuart Street
  • City: Boston
  • State: Massachusetts
  • Country: United States
  • Zip/Postal Code: 02116
  • Contact Email: jenny.barlow@hansonwade.com
  • Contact Name: Jenny Barlow
  • Listed: December 31, 2015 7:19 pm
  • Expires: This ad has expired

Description

As the frenzy of preclinical and clinical programs continues, it is critical to take a step back and work out what is working and what is not. At this year’s ICI Boston we are gathering the field’s experts to review the latest research and clinical success of checkpoint modulators.

With insights and fresh data from early validation through to clinical strategy we’ve curated the most valuable and important case studies from the last 12 months.

Working with the likes of BMS, Merck, AstraZeneca and EMD Serono to understand the biggest challenges in checkpoint inhibition; the agenda is designed to cut through the hype and share real insights and how the industry’s best are effectively progressing their pipelines through the clinic and onto the market.

ICI Boston will help you leverage the new understanding of pathway biology and biomarker strategy in the development of your checkpoint drugs. Listen to data and experiences from 31 experts in immune checkpoint regulation as they share what has speed their programs to success so far.

Focusing on the translational challenges that drug developers face in bringing these therapies there will be information shared on the most pressing industry challenges:

-Hear about discovery and validation of pathway biologies beyond PD-1
-Review immuno-oncology combinations that deliver more robust and durable patient responses
-Learn aboutnovel biomarkers for patient stratification
-Appreciate the commercial strategy of the most advanced players and assess market opportunities for the year to come

Looking for a job as an event professional? Click Here

Ad Reference ID: 83556791c18805bc

Sponsored Links

Leave a Reply

To inquire about this ad listing, complete the form below to send a message to the ad poster.

Whats New